David F Melcher has bought stock on 9 days since May 2018

David F. Melcher is a corporate director and retired U.S. Army lieutenant general who serves as Non-Executive Chairman of the Board at Embecta Corp. (Nasdaq: EMBC), the diabetes-focused medical supplies company spun off from BD (Becton, Dickinson and Company).( He has been a director of Embecta since the board’s inception in 2022 and has recently reported insider share transactions in the company’s stock, reflecting his role as a corporate insider.( Melcher has notified Embecta that, due to external commitments, he will not stand for re-election and will retire from the board at the company’s 2026 annual stockholder meeting.(

Prior to his Embecta role, Melcher served as a director of BD following its acquisition of C.R. Bard in 2017, having previously been a Bard director since 2014.( He retired in 2017 as president and CEO of the Aerospace Industries Association, a major trade association for aerospace and defense manufacturers.( From 2011 to 2015, he was CEO, president and a director of Exelis, a NYSE-listed defense and information solutions company, after earlier leading ITT Defense and Information Solutions.( Melcher’s corporate governance portfolio also includes service as an independent director and later vice chairman of USAA, as well as membership on the Board of Managers of GM Defense.( Before entering industry, he completed 32 years of distinguished service in the U.S. Army, attaining the rank of lieutenant general and receiving high-level decorations.( He is a registered professional civil engineer and holds a Bachelor of Science degree from the U.S. Military Academy at West Point, along with graduate study at Shippensburg University of Pennsylvania.(

Written by Perplexity from public sources.